Gene and cell therapy group Oxford Biomedica has launched a full scope adeno-associated viruses manufacturing and innovation business in Boston, following the closing of its deal with Homology.
The group says its new Oxford Biomedica Solutions business is fully operational and offers a proprietary ‘plug and play’ platform that is capable of achieving both high titre and high product quality vector for customers.
The platform has already been proven with three separate new product applications, and the process has been run successfully at representative scale more than 600 times.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “We are delighted to have closed this transaction. Oxford Biomedica is transforming into an innovative global viral vector leader that provides solutions to cell and gene therapy biotech and biopharma companies for their process development and manufacturing needs. Our ambition is to become a leading partner of choice with advanced capabilities across key vector types.
“This transaction also sees us form our first US operating subsidiary, located close to customers, talent, innovation in academia and pools of capital, which will enhance our market leadership position working across key viral vector types. Oxford Biomedica is in a strong position to enable our customers to bring their new medicines to many more patients and change their lives.”
Tim Kelly, CEO of Oxford Biomedica Solutions, said: “The team is excited to be able to offer this unique platform capability to help more companies and ultimately patients. The combination of our deep expertise, innovative platform technology, and dynamic team will make for a truly differentiated capability that I am confident will contribute to addressing some of the challenges being encountered in the cell and gene therapy space today, an area Oxford Biomedica knows well.”